Clinical trial · Observational
Molecular Tumor Board at the Center for Personalized Medicine Tübingen
Molecular Tumor Board at the Center for Personalized Medicine Tübingen: a Prospective Observational Study
NCT03503149CI-TRIAL-00032585MTB@ZPMrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Molecular Tumor Board at the Center for Personalized Medicine
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Cancer | Malignant Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| no intervention | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Progression-free survival
- timeFrame
- 6 months
- description
- Progression-free survival
Secondary outcomes (1)
- measure
- Overall survival
- timeFrame
- an average of 1 year
- description
- Progression-free survival
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria:
* Given informed consent ("broad consent" of the University Hospital Tübingen)
* ≥ 18 years of age
* Clinical indication for a referral to Molecular Tumor Board by the treating physician
Exclusion Criteria:
* The MTB assists the referring physician with the interpretation and the use of tumor molecular profiling data for deciding on a therapeutic strategy. Therefore, this board is confined to cancer patients and cannot provide any service for non-cancer patientsReferences
Publications (0)
Data not yet available
No reference posted for this study.